Next-generation treatments for mental disorders

Science Translational Medicine

Volumn 4, Issue 155, 2012, Pages

  Insel, Thomas R ^a  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID B RECEPTOR STIMULATING AGENT; AMG 747; AZD 6765; BIOLOGICAL MARKER; BRAIN DERIVED NEUROTROPHIC FACTOR; CARBETOCIN; CHLORPROMAZINE; CNTNAP2 PROTEIN; CYCLOSERINE; FIBROBLAST GROWTH FACTOR 2; IPRONIAZID; KETAMINE; LITHIUM DERIVATIVE; MACROPHAGE MIGRATION INHIBITION FACTOR; METABOTROPIC RECEPTOR ANTAGONIST; NEUREXIN; NEURITIN; NEUROLEPTIC AGENT; OCTAHYDRO 4 HYDROXY 4 [(3 METHYLPHENYL)ETHYNYL] 1H INDOLE 1 CARBOXYLIC ACID METHYL ESTER; OXYTOCIN; PROTEIN P11; PROTEIN SHANK 3; RG 7314; RO 4917523; RO 5028442; SCOPOLAMINE; STX 107; STX 207; SYNAPSE RECEPTOR; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASOPRESSIN;

ALLELE; ANTIDEPRESSANT ACTIVITY; ANTIINFLAMMATORY ACTIVITY; AUTISM; BCL11A GENE; BIPOLAR DISORDER; BRAIN DEPTH STIMULATION; COGNITIVE DEFECT; COGNITIVE THERAPY; DEPRESSION; DRUG ACTIVITY; DRUG MARKETING; DRUG RESEARCH; EXPERIMENTAL MEDICINE; GENE; GENE SEQUENCE; GENE TARGETING; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENETICS; HUMAN; MENTAL DISEASE; MORBIDITY; MORTALITY; NERVE CELL PLASTICITY; NONHUMAN; PATHOPHYSIOLOGY; PHOBIA; PLURIPOTENT STEM CELL; PRIORITY JOURNAL; PUBLIC HEALTH; REPRODUCIBILITY; REVIEW; SCHIZOPHRENIA; SICKLE CELL ANEMIA; SOCIAL COGNITION; SUICIDE; TRANSCRANIAL MAGNETIC STIMULATION; WORKING MEMORY;

ANTIDEPRESSIVE AGENTS; DRUG DISCOVERY; HUMANS; MENTAL DISORDERS; NEURONAL PLASTICITY; PSYCHIATRY;

EID: 84867475329     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.3004873     Document Type: Review

References (85)

1. T. R. Insel, E. M. Scolnick, Cure therapeutics and strategic prevention: Raising the bar for mental health research. Mol. Psychiatry 11, 11-17 (2006).
2. I. Kola, J. Landis, Can the pharmaceutical industry reduce attrition rates? Nat. Rev. Drug Discov. 3, 711-715 (2004).
3. A. A. Nierenberg, The perfect storm: CNS drug development in trouble. CNS Spectr. 15, 282-283 (2010).
4. G. Miller, Is pharma running out of brainy ideas? Science 329, 502-504 (2010).
5. IMS Health Inc, Biopharma Forecasts and Trends. http://www.imshealth.com (2010).
6. R. C. Kessler, O. Demler, R. G. Frank, M. Olfson, H. A. Pincus, E. E. Walters, P. Wang, K. B. Wells, A. M. Zaslavsky, Prevalence and treatment of mental disorders, 1990 to 2003. N. Engl. J. Med. 352, 2515-2523 (2005).
7. Centers for Disease Control and Prevention, National Center for Injury Prevention and Control, Web-based Injury Statistics Query and Reporting System (WISQARS), http://www.cdc.gov/ncipc/wisqars/default.htm.
8. H. U. Wittchen, F. Jacobi, J. Rehm, A. Gustavsson, M. Svensson, B. Jönsson, J. Olesen, C. Allgulander, J. Alonso, C. Faravelli, L. Fratiglioni, P. Jennum, R. Lieb, A. Maercker, J. van Os, M. Preisig, L. Salvador-Carulla, R. Simon, H. C. Steinhausen, The size and burden of mental disorders and other disorders of the brain in Europe 2010. Eur. Neuropsychopharmacol. 21, 655-679 (2011).
9. R. Layard, How Mental Health Loses Out in the NHS. (2012). http://cep.lse.ac.uk/-new/research/mentalhealth/
10. A. J. Rush, M. H. Trivedi, S. R. Wisniewski, A. A. Nierenberg, J. W. Stewart, D. Warden, G. Niederehe, M. E. Thase, P. W. Lavori, B. D. Lebowitz, P. J. McGrath, J. F. Rosenbaum, H. A. Sackeim, D. J. Kupfer, J. Luther, M. Fava, Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: A STAR*D report. Am. J. Psychiatry 163, 1905-1917 (2006).
11. M. H. Trivedi, A. J. Rush, S. R. Wisniewski, A. A. Nierenberg, D. Warden, L. Ritz, G. Norquist, R. H. Howland, B. Lebowitz, P. J. McGrath, K. Shores-Wilson, M. M. Biggs, G. K. Balasubramani, M. Fava, STAR*D Study Team, Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: Implications for clinical practice. Am. J. Psychiatry 163, 28-40 (2006).
12. J. A. Lieberman, T. S. Stroup, J. P. McEvoy, M. S. Swartz, R. A. Rosenheck, D. O. Perkins, R. S. Keefe, S. M. Davis, C. E. Davis, B. D. Lebowitz, J. Severe, J. K. Hsiao, Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators, Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N. Engl. J. Med. 353, 1209-1223 (2005).
13. S. E. Hyman, W. S. Fenton, Medicine. What are the right targets for psychopharmacology? Science 299, 350-351 (2003).
14. T. A. Manolio, Genomewide association studies and assessment of the risk of disease. N. Engl. J. Med. 363, 166-176 (2010).
15. E. S. Lander, Initial impact of the sequencing of the human genome. Nature 470, 187-197 (2011).
16. V. Vacic, S. McCarthy, D. Malhotra, F. Murray, H. H. Chou, A. Peoples, V. Makarov, S. Yoon, A. Bhandari, R. Corominas, L. M. Iakoucheva, O. Krastoshevsky, V. Krause, V. Larach-Walters, D. K. Welsh, D. Craig, J. R. Kelsoe, E. S. Gershon, S. M. Leal, M. Dell Aquila, D. W. Morris, M. Gill, A. Corvin, P. A. Insel, J. McClellan, M. C. King, M. Karayiorgou, D. L. Levy, L. E. DeLisi, J. Sebat, Duplications of the neuropeptide receptor gene VIPR2 confer significant risk for schizophrenia. Nature 471, 499-503 (2011).
17. F. Zhang, W. Gu, M. E. Hurles, J. R. Lupski, Copy number variation in human health, disease, and evolution. Annu. Rev. Genomics Hum. Genet. 10, 451-481 (2009).
18. J. Sebat, B. Lakshmi, D. Malhotra, J. Troge, C. Lese-Martin, T. Walsh, B. Yamrom, S. Yoon, A. Krasnitz, J. Kendall, A. Leotta, D. Pai, R. Zhang, Y. H. Lee, J. Hicks, S. J. Spence, A. T. Lee, K. Puura, T. Lehtimäki, D. Ledbetter, P. K. Gregersen, J. Bregman, J. S. Sutcliffe, V. Jobanputra, W. Chung, D. Warburton, M. C. King, D. Skuse, D. H. Geschwind, T. C. Gilliam, K. Ye, M. Wigler, Strong association of de novo copy number mutations with autism. Science 316, 445-449 (2007).
19. T. Walsh, J. M. McClellan, S. E. McCarthy, A. M. Addington, S. B. Pierce, G. M. Cooper, A. S. Nord, M. Kusenda, D. Malhotra, A. Bhandari, S. M. Stray, C. F. Rippey, P. Roccanova, V. Makarov, B. Lakshmi, R. L. Findling, L. Sikich, T. Stromberg, B. Merriman, N. Gogtay, P. Butler, K. Eckstrand, L. Noory, P. Gochman, R. Long, Z. Chen, S. Davis, C. Baker, E. E. Eichler, P. S. Meltzer, S. F. Nelson, A. B. Singleton, M. K. Lee, J. L. Rapoport, M. C. King, J. Sebat, Rare structural variants disrupt multiple genes in neurodevelopmental pathways in schizophrenia. Science 320, 539-543 (2008).
20. J. Elia, J. T. Glessner, K. Wang, N. Takahashi, C. J. Shtir, D. Hadley, P. M. Sleiman, H. Zhang, C. E. Kim, R. Robison, G. J. Lyon, J. H. Flory, J. P. Bradfield, M. Imielinski, C. Hou, E. C. Frackelton, R. M. Chiavacci, T. Sakurai, C. Rabin, F. A. Middleton, K. A. Thomas, M. Garris, F. Mentch, C. M. Freitag, H. C. Steinhausen, A. A. Todorov, A. Reif, A. Rothenberger, B. Franke, E. O. Mick, H. Roeyers, J. Buitelaar, K. P. Lesch, T. Banaschewski, R. P. Ebstein, F. Mulas, R. D. Oades, J. Sergeant, E. Sonuga-Barke, T. J. Renner, M. Romanos, J. Romanos, A. Warnke, S. Walitza, J. Meyer, H. Pálmason, C. Seitz, S. K. Loo, S. L. Smalley, J. Biederman, L. Kent, P. Asherson, R. J. Anney, J. W. Gaynor, P. Shaw, M. Devoto, P. S. White, S. F. Grant, J. D. Buxbaum, J. L. Rapoport, N. M. Williams, S. F. Nelson, S. V. Faraone, H. Hakonarson, Genome-wide copy number variation study associates metabotropic glutamate receptor gene networks with attention deficit hyperactivity disorder. Nat. Genet. 44, 78-84 (2012).
21. F. S. Collins, Reengineering translational science: The time is right. Sci. Transl. Med. 3, 90cm17 (2011).
22. V. G. Sankaran, T. F. Menne, J. Xu, T. E. Akie, G. Lettre, B. Van Handel, H. K. Mikkola, J. N. Hirschhorn, A. B. Cantor, S. H. Orkin, Human fetal hemoglobin expression is regulated by the developmental stage-specific repressor BCL11A. Science 322, 1839-1842 (2008).
23. A. K. Soutar, R. P. Naoumova, Mechanisms of disease: Genetic causes of familial hypercholesterolemia. Nat. Clin. Pract. Cardiovasc. Med. 4, 214-225 (2007).
24. J. K. Baillie, M. W. Barnett, K. R. Upton, D. J. Gerhardt, T. A. Richmond, F. De Sapio, P. M. Brennan, P. Rizzu, S. Smith, M. Fell, R. T. Talbot, S. Gustincich, T. C. Freeman, J. S. Mattick, D. A. Hume, P. Heutink, P. Carninci, J. A. Jeddeloh, G. J. Faulkner, Somatic retrotransposition alters the genetic landscape of the human brain. Nature 479, 534-537 (2011).
25. A. Poduri, G. D. Evrony, X. Cai, P. C. Elhosary, R. Beroukhim, M. K. Lehtinen, L. B. Hills, E. L. Heinzen, A. Hill, R. S. Hill, B. J. Barry, B. F. Bourgeois, J. J. Riviello, A. J. Barkovich, P. M. Black, K. L. Ligon, C. A. Walsh, Somatic activation of AKT3 causes hemispheric developmental brain malformations. Neuron 74, 41-48 (2012).
26. S. Ripke, A. R. Sanders, K. S. Kendler, D. F. Levinson, P. Sklar, P. A. Holmans, D. Y. Lin, J. Duan, R. A. Ophoff, O. A. Andreassen, E. Scolnick, S. Cichon, D. St Clair, A. Corvin, H. Gurling, T. Werge, D. Rujescu, D. H. Blackwood, C. N. Pato, A. K. Malhotra, S. Purcell, F. Dudbridge, B. M. Neale, L. Rossin, P. M. Visscher, D. Posthuma, D. M. Ruderfer, A. Fanous, H. Stefansson, S. Steinberg, B. J. Mowry, V. Golimbet, M. De Hert, E. G. Jönsson, I. Bitter, O. P. Pietiläinen, D. A. Collier, S. Tosato, I. Agartz, M. Albus, M. Alexander, R. L. Amdur, F. Amin, N. Bass, S. E. Bergen, D. W. Black, A. D. Børglum, M. A. Brown, R. Bruggeman, N. G. Buccola, W. F. Byerley, W. Cahn, R. M. Cantor, V. J. Carr, S. V. Catts, K. Choudhury, C. R. Cloninger, P. Cormican, N. Craddock, P. A. Danoy, S. Datta, L. de Haan, D. Demontis, D. Dikeos, S. Djurovic, P. Donnelly, G. Donohoe, L. Duong, S. Dwyer, A. Fink-Jensen, R. Freedman, N. B. Freimer, M. Friedl, L. Georgieva, I. Giegling, M. Gill, B. Glenthøj, S. Godard, M. Hamshere, M. Hansen, T. Hansen, A. M. Hartmann, F. A. Henskens, D. M. Hougaard, C. M. Hultman, A. Ingason, A. V. Jablensky, K. D. Jakobsen, M. Jay, G. Jürgens, R. S. Kahn, M. C. Keller, G. Kenis, E. Kenny, Y. Kim, G. K. Kirov, H. Konnerth, B. Konte, L. Krabbendam, R. Krasucki, V. K. Lasseter, C. Laurent, J. Lawrence, T. Lencz, F. B. Lerer, K. Y. Liang, P. Lichtenstein, J. A. Lieberman, D. H. Linszen, J. Lönnqvist, C. M. Loughland, A. W. Maclean, B. S. Maher, W. Maier, J. Mallet, P. Malloy, M. Mattheisen, M. Mattingsdal, K. A. McGhee, J. J. McGrath, A. McIntosh, D. E. McLean, A. McQuillin, I. Melle, P. T. Michie, V. Milanova, D. W. Morris, O. Mors, P. B. Mortensen, V. Moskvina, P. Muglia, I. Myin-Germeys, D. A. Nertney, G. Nestadt, J. Nielsen, I. Nikolov, M. Nordentoft, N. Norton, M. M. Nöthen, C. T. O'Dushlaine, A. Olincy, L. Olsen, F. A. O'Neill, T. F. Orntoft, M. J. Owen, C. Pantelis, G. Papadimitriou, M. T. Pato, L. Peltonen, H. Petursson, B. Pickard, J. Pimm, A. E. Pulver, V. Puri, D. Quested, E. M. Quinn, H. B. Rasmussen, J. M. Réthelyi, R. Ribble, M. Rietschel, B. P. Riley, M. Ruggeri, U. Schall, T. G. Schulze, S. G. Schwab, R. J. Scott, J. Shi, E. Sigurdsson, J. M. Silverman, C. C. Spencer, K. Stefansson, A. Strange, E. Strengman, T. S. Stroup, J. Suvisaari, L. Terenius, S. Thirumalai, J. H. Thygesen, S. Timm, D. Toncheva, E. van den Oord, J. van Os, R. van Winkel, J. Veldink, D. Walsh, A. G. Wang, D. Wiersma, D. B. Wildenauer, H. J. Williams, N. M. Williams, B. Wormley, S. Zammit, P. F. Sullivan, M. C. O'Donovan, M. J. Daly, P. V. Gejman, Schizophrenia Psychiatric Genome-Wide Association Study (GWAS) Consortium, Genome-wide association study identifies five new schizophrenia loci. Nat. Genet. 43, 969-976 (2011).
27. P. Sklar, S. Ripke, L. J. Scott, O. A. Andreassen, S. Cichon, N. Craddock, H. J. Edenberg, J. I. Nurnberger Jr., M. Rietschel, D. Blackwood, A. Corvin, M. Flickinger, W. Guan, M. Mattingsdal, A. McQuillin, P. Kwan, T. F. Wienker, M. Daly, F. Dudbridge, P. A. Holmans, D. Lin, M. Burmeister, T. A. Greenwood, M. L. Hamshere, P. Muglia, E. N. Smith, P. P. Zandi, C. M. Nievergelt, R. McKinney, P. D. Shilling, N. J. Schork, C. S. Bloss, T. Foroud, D. L. Koller, E. S. Gershon, C. Liu, J. A. Badner, W. A. Scheftner, W. B. Lawson, E. A. Nwulia, M. Hipolito, W. Coryell, J. Rice, W. Byerley, F. J. McMahon, T. G. Schulze, W. Berrettini, F. W. Lohoff, J. B. Potash, P. B. Mahon, M. G. McInnis, S. Zöllner, P. Zhang, D. W. Craig, S. Szelinger, T. B. Barrett, R. Breuer, S. Meier, J. Strohmaier, S. H. Witt, F. Tozzi, A. Farmer, P. McGuffin, J. Strauss, W. Xu, J. L. Kennedy, J. B. Vincent, K. Matthews, R. Day, M. A. Ferreira, C. O'Dushlaine, R. Perlis, S. Raychaudhuri, D. Ruderfer, P. L. Hyoun, J. W. Smoller, J. Li, D. Absher, R. C. Thompson, F. G. Meng, A. F. Schatzberg, W. E. Bunney, J. D. Barchas, E. G. Jones, S. J. Watson, R. M. Myers, H. Akil, M. Boehnke, K. Chambert, J. Moran, E. Scolnick, S. Djurovic, I. Melle, G. Morken, M. Gill, D. Morris, E. Quinn, T. W. Mühleisen, F. A. Degenhardt, M. Mattheisen, J. Schumacher, W. Maier, M. Steffens, P. Propping, M. M. Nöthen, A. Anjorin, N. Bass, H. Gurling, R. Kandaswamy, J. Lawrence, K. McGhee, A. McIntosh, A. W. McLean, W. J. Muir, B. S. Pickard, G. Breen, D. St Clair, S. Caesar, K. Gordon-Smith, L. Jones, C. Fraser, E. K. Green, D. Grozeva, I. R. Jones, G. Kirov, V. Moskvina, I. Nikolov, M. C. O'Donovan, M. J. Owen, D. A. Collier, A. Elkin, R. Williamson, A. H. Young, I. N. Ferrier, K. Stefansson, H. Stefansson, T. Thornorgeirsson, S. Steinberg, O. Gustafsson, S. E. Bergen, V. Nimgaonkar, C. Hultman, M. Landén, P. Lichtenstein, P. Sullivan, M. Schalling, U. Osby, L. Backlund, L. Frisén, N. Langstrom, S. Jamain, M. Leboyer, B. Etain, F. Bellivier, H. Petursson, E. Sigur Sson, B. Müller-Mysok, S. Lucae, M. Schwarz, P. R. Schofield, N. Martin, G. W. Montgomery, M. Lathrop, H. Oskarsson, M. Bauer, A. Wright, P. B. Mitchell, M. Hautzinger, A. Reif, J. R. Kelsoe, S. M. Purcell; Psychiatric GWAS Consortium Bipolar Disorder Working Group, Large-scale genome-wide association analysis of bipolar disorder identifies a new susceptibility locus near ODZ4. Nat. Genet. 43, 977-983 (2011).
28. S. J. Huffaker, J. Chen, K. K. Nicodemus, F. Sambataro, F. Yang, V. Mattay, B. K. Lipska, T. M. Hyde, J. Song, D. Rujescu, I. Giegling, K. Mayilyan, M. J. Proust, A. Soghoyan, G. Caforio, J. H. Callicott, A. Bertolino, A. Meyer-Lindenberg, J. Chang, Y. Ji, M. F. Egan, T. E. Goldberg, J. E. Kleinman, B. Lu, D. R. Weinberger, A primate-specific, brain isoform of KCNH2 affects cortical physiology, cognition, neuronal repolarization and risk of schizophrenia. Nat. Med. 15, 509-518 (2009).
29. J. Y. Kim, X. Duan, C. Y. Liu, M. H. Jang, J. U. Guo, N. Powanpongkul, E. Kang, H. Song, G. L. Ming, DISC1 regulates new neuron development in the adult brain via modulation of AKT-mTOR signaling through KIAA1212. Neuron 63, 761-773 (2009).
30. J. Y. Kim, C. Y. Liu, F. Zhang, X. Duan, Z. Wen, J. Song, E. Feighery, B. Lu, D. Rujescu, D. St Clair, K. Christian, J. H. Callicott, D. R. Weinberger, H. Song, G. L. Ming, Interplay between DISC1 and GABA signaling regulates neurogenesis in mice and risk for schizophrenia. Cell 148, 1051-1064 (2012).
31. A. J. Law, Y. Wang, Y. Sei, P. O'Donnell, P. Piantadosi, F. Papaleo, R. E. Straub, W. Huang, C. J. Thomas, R. Vakkalanka, A. D. Besterman, B. K. Lipska, T. M. Hyde, P. J. Harrison, J. E. Kleinman, D. R. Weinberger, Neuregulin 1-ErbB4-PI3K signaling in schizophrenia and phosphoinositide 3-kinase-p110δ inhibition as a potential therapeutic strategy. Proc. Natl. Acad. Sci. U.S.A. 109, 12165-12170 (2012).
32. M. A. Ferreira, M. C. O'Donovan, Y. A. Meng, I. R. Jones, D. M. Ruderfer, L. Jones, J. Fan, G. Kirov, R. H. Perlis, E. K. Green, J. W. Smoller, D. Grozeva, J. Stone, I. Nikolov, K. Chambert, M. L. Hamshere, V. L. Nimgaonkar, V. Moskvina, M. E. Thase, S. Caesar, G. S. Sachs, J. Franklin, K. Gordon-Smith, K. G. Ardlie, S. B. Gabriel, C. Fraser, B. Blumenstiel, M. Defelice, G. Breen, M. Gill, D. W. Morris, A. Elkin, W. J. Muir, K. A. McGhee, R. Williamson, D. J. MacIntyre, A. W. MacLean, C. D. St, M. Robinson, M. Van Beck, A. C. Pereira, R. Kandaswamy, A. McQuillin, D. A. Collier, N. J. Bass, A. H. Young, J. Lawrence, I. N. Ferrier, A. Anjorin, A. Farmer, D. Curtis, E. M. Scolnick, P. McGuffin, M. J. Daly, A. P. Corvin, P. A. Holmans, D. H. Blackwood, H. M. Gurling, M. J. Owen, S. M. Purcell, P. Sklar, N. Craddock, Wellcome Trust Case Control Consortium, Collaborative genome-wide association analysis supports a role for ANK3 and CACNA1C in bipolar disorder. Nat. Genet. 40, 1056-1058 (2008).
33. Y. Sakai, C. A. Shaw, B. C. Dawson, D. V. Dugas, Z. Al-Mohtaseb, D. E. Hill, H. Y. Zoghbi, Protein interactome reveals converging molecular pathways among autism disorders. Sci. Transl. Med. 3, 86ra49 (2011).
34. O. Peñagarikano, B. S. Abrahams, E. I. Herman, K. D. Winden, A. Gdalyahu, H. Dong, L. I. Sonnenblick, R. Gruver, J. Almajano, A. Bragin, P. Golshani, J. T. Trachtenberg, E. Peles, D. H. Geschwind, Absence of CNTNAP2 leads to epilepsy, neuronal migration abnormalities, and core autism-related deficits. Cell 147, 235-246 (2011).
35. H. G. Kim, S. Kishikawa, A. W. Higgins, I. S. Seong, D. J. Donovan, Y. Shen, E. Lally, L. A. Weiss, J. Najm, K. Kutsche, M. Descartes, L. Holt, S. Braddock, R. Troxell, L. Kaplan, F. Volkmar, A. Klin, K. Tsatsanis, D. J. Harris, I. Noens, D. L. Pauls, M. J. Daly, M. E. MacDonald, C. C. Morton, B. J. Quade, J. F. Gusella, Disruption of neurexin 1 associated with autism spectrum disorder. Am. J. Hum. Genet. 82, 199-207 (2008).
36. C. A. Turner, S. M. Clinton, R. C. Thompson, S. J. Watson Jr., H. Akil, Fibroblast growth factor-2 (FGF2) augmentation early in life alters hippocampal development and rescues the anxiety phenotype in vulnerable animals. Proc. Natl. Acad. Sci. U.S.A. 108, 8021-8025 (2011).
37. P. Svenningsson, K. Chergui, I. Rachleff, M. Flajolet, X. Zhang, M. El Yacoubi, J. M. Vaugeois, G. G. Nomikos, P. Greengard, Alterations in 5-HT1B receptor function by p11 in depression-like states. Science 311, 77-80 (2006).
38. B. Alexander, J. Warner-Schmidt, T. Eriksson, C. Tamminga, M. Arango-Lievano, S. Ghose, M. Vernov, M. Stavarache, S. Musatov, M. Flajolet, P. Svenningsson, P. Greengard, M. G. Kaplitt, Reversal of depressed behaviors in mice by p11 gene therapy in the nucleus accumbens. Sci. Transl. Med. 2, 54ra76 (2010).
39. H. Y. Moon, S. H. Kim, Y. R. Yang, P. Song, H. S. Yu, H. G. Park, O. Hwang, W. Lee-Kwon, J. K. Seo, D. Hwang, J. H. Choi, R. Bucala, S. H. Ryu, Y. S. Kim, P. G. Suh, Macrophage migration inhibitory factor mediates the antidepressant actions of voluntary exercise. Proc. Natl. Acad. Sci. U.S.A. 109, 13094-13099 (2012).
40. H. Son, M. Banasr, M. Choi, S. Y. Chae, P. Licznerski, B. Lee, B. Voleti, N. Li, A. Lepack, N. M. Fournier, K. R. Lee, I. Y. Lee, J. Kim, J. H. Kim, Y. H. Kim, S. J. Jung, R. S. Duman, Neuritin produces antidepressant actions and blocks the neuronal and behavioral deficits caused by chronic stress. Proc. Natl. Acad. Sci. U.S.A. 109, 11378-11383 (2012).
41. A. A. Pieper, S. Xie, E. Capota, S. J. Estill, J. Zhong, J. M. Long, G. L. Becker, P. Huntington, S. E. Goldman, C. H. Shen, M. Capota, J. K. Britt, T. Kotti, K. Ure, D. J. Brat, N. S. Williams, K. S. MacMillan, J. Naidoo, L. Melito, J. Hsieh, J. De Brabander, J. M. Ready, S. L. McKnight, Discovery of a proneurogenic, neuroprotective chemical. Cell 142, 39-51 (2010).
42. B. A. Samuels, R. Hen, Neurogenesis and affective disorders. Eur. J. Neurosci. 33, 1152-1159 (2011).
43. T. R. Insel, Rethinking schizophrenia. Nature 468, 187-193 (2010).
44. K. J. Brennand, A. Simone, J. Jou, C. Gelboin-Burkhart, N. Tran, S. Sangar, Y. Li, Y. Mu, G. Chen, D. Yu, S. McCarthy, J. Sebat, F. H. Gage, Modelling schizophrenia using human induced pluripotent stem cells. Nature 473, 221-225 (2011).
45. S. P. Paşca, T. Portmann, I. Voineagu, M. Yazawa, A. Shcheglovitov, A. M. Paşca, B. Cord, T. D. Palmer, S. Chikahisa, S. Nishino, J. A. Bernstein, J. Hallmayer, D. H. Geschwind, R. E. Dolmetsch, Using iPSC-derived neurons to uncover cellular phenotypes associated with Timothy syndrome. Nat. Med. 17, 1657-1662 (2011).
46. R. Min, T. Nevian, Astrocyte signaling controls spike timing-dependent depression at neocortical synapses. Nat. Neurosci. 15, 746-753 (2012).
47. N. Diazgranados, L. Ibrahim, N. E. Brutsche, A. Newberg, P. Kronstein, S. Khalife, W. A. Kammerer, Z. Quezado, D. A. Luckenbaugh, G. Salvadore, R. Machado-Vieira, H. K. Manji, C. A. Zarate Jr., A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression. Arch. Gen. Psychiatry 67, 793-802 (2010).
48. N. Li, B. Lee, R. J. Liu, M. Banasr, J. M. Dwyer, M. Iwata, X. Y. Li, G. Aghajanian, R. S. Duman, mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science 329, 959-964 (2010).
49. R. S. Duman, N. Li, R. J. Liu, V. Duric, G. Aghajanian, Signaling pathways underlying the rapid antidepressant actions of ketamine. Neuropharmacology 62, 35-41 (2012).
50. Morbidity and Mortality Weekly Report (MMWR) Surveillance Summaries, Vol. 58 1-20. Centers for Disease Control and Prevention (2009).
51. P. Kirsch, C. Esslinger, Q. Chen, D. Mier, S. Lis, S. Siddhanti, H. Gruppe, V. S. Mattay, B. Gallhofer, A. Meyer-Lindenberg, Oxytocin modulates neural circuitry for social cognition and fear in humans. J. Neurosci. 25, 11489-11493 (2005).
52. G. J. Dumont, F. C. Sweep, R. van der Steen, R. Hermsen, A. R. Donders, D. J. Touw, J. M. van Gerven, J. K. Buitelaar, R. J. Verkes, Increased oxytocin concentrations and prosocial feelings in humans after ecstasy (3,4-methylenedioxymethamphetamine) administration. Soc. Neurosci. 4, 359-366 (2009).
53. C. Henderson, L. Wijetunge, M. N. Kinoshita, M. Shumway, R. S. Hammond, F. R. Postma, C. Brynczka, R. Rush, A. Thomas, R. Paylor, S. T. Warren, P. W. Vanderklish, P. C. Kind, R. L. Carpenter, M. F. Bear, A. M. Healy, Reversal of disease-related pathologies in the fragile X mouse model by selective activation of GABAB receptors with arbaclofen. Sci. Transl. Med. 4, 152ra128 (2012).
54. E. M. Berry-Kravis, D. Hessl, B. Rathmell, P. Zarevics, M. Cherubini, K. Walton-Bowen, Y. Mu, D. V. Nguyen, J. Gonzalez-Heydrich, P. P. Wang, R. L. Carpenter, M. F. Bear, R. J. Hagerman, Effects of STX209 (Arbaclofen) on neurobehavioral function in children and adults with fragile X syndrome: A randomized, controlled, phase 2 trial. Sci. Transl. Med. 4, 152ra127 (2012).
55. S. Jacquemont, A. Curie, V. des Portes, M. G. Torrioli, E. Berry-Kravis, R. J. Hagerman, F. J. Ramos, K. Cornish, Y. He, C. Paulding, G. Neri, F. Chen, N. Hadjikhani, D. Martinet, J. Meyer, J. S. Beckmann, K. Delange, A. Brun, G. Bussy, F. Gasparini, T. Hilse, A. Floesser, J. Branson, G. Bilbe, D. Johns, B. Gomez-Mancilla, Epigenetic modification of the FMR1 gene in fragile X syndrome is associated with differential response to the mGluR5 antagonist AFQ056. Sci Transl. Med. 3, 64ra1 (2011).
56. T. R. Insel, Faulty circuits. Sci. Am. 302, 44-51 (2010).
57. K. Deisseroth, Optogenetics and psychiatry: Applications, challenges, and opportunities. Biol. Psychiatry 71, 1030-1032 (2012).
58. M. A. Rosa, S. H. Lisanby, Somatic treatments for mood disorders. Neuropsychopharmacology 37, 102-116 (2012).
59. P. E. Holtzheimer, M. E. Kelley, R. E. Gross, M. M. Filkowski, S. J. Garlow, A. Barrocas, D. Wint, M. C. Craighead, J. Kozarsky, R. Chismar, J. L. Moreines, K. Mewes, P. R. Posse, D. A. Gutman, H. S. Mayberg, Subcallosal cingulate deep brain stimulation for treatment-resistant unipolar and bipolar depression. Arch. Gen. Psychiatry 69, 150-158 (2012).
60. K. Subramaniam, T. L. Luks, M. Fisher, G. V. Simpson, S. Nagarajan, S. Vinogradov, Computerized cognitive training restores neural activity within the reality monitoring network in schizophrenia. Neuron 73, 842-853 (2012).
61. S. Eldar, A. Apter, D. Lotan, K. P. Edgar, R. Naim, N. A. Fox, D. S. Pine, Y. Bar-Haim, Attention bias modification treatment for pediatric anxiety disorders: A randomized controlled trial. Am. J. Psychiatry 169, 213-220 (2012).
62. T. Nordgreen, O. E. Havik, L. G. Ost, T. Furmark, P. Carlbring, G. Andersson, Outcome predictors in guided and unguided self-help for social anxiety disorder. Behav. Res. Ther. 50, 13-21 (2012).
63. T. P. Medicine, Building a Knowledge Network for Biomedical Research and a New Taxonomy of Disease. (National Research Council, The National Academies Press, 2011).
64. C. L. Raison, R. E. Rutherford, B. J. Woolwine, C. Shuo, P. Schettler, D. F. Drake, E. Haroon, A. H. Miller, A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: The role of baseline inflammatory biomarkers. Arch. Gen. Psychiatry 1-11 (2012).
65. J. M. Broadway, P. E. Holtzheimer, M. R. Hilimire, N. A. Parks, J. E. Devylder, H. S. Mayberg, P. M. Corballis, Frontal theta cordance predicts 6-month antidepressant response to subcallosal cingulate deep brain stimulation for treatment-resistant depression: A pilot study. Neuropsychopharmacology 37, 1764-1772 (2012).
66. L. M. Williams, A. J. Rush, S. H. Koslow, S. R. Wisniewski, N. J. Cooper, C. B. Nemeroff, A. F. Schatzberg, E. Gordon, International Study to Predict Optimized Treatment for Depression (iSPOT-D), A randomized clinical trial: Rationale and protocol. Trials 12, 4-21 (2011).
67. B. W. Dunlop, E. B. Binder, J. F. Cubells, M. G. Goodman, M. E. Kelley, B. Kinkead, M. Kutner, C. B. Nemeroff, D. J. Newport, M. J. Owens, T. W. Pace, J. C. Ritchie, V. Aponte Rivera, D. Westen, W. E. Craighead, H. S. Mayberg, Predictors of remission in depression to individual and combined treatments (PReDICT): Study protocol for a randomized controlled trial. Trials 13, 106 (2012).
68. T. R. Insel, B. Cuthbert, M. Garvey, R. Heinssen, D. S. Pine, K. Quinn, C. Sanislow, P. Wang, Research domain criteria (RDoC): Toward a new classification framework for research on mental disorders. Am. J. Psychiatry 167, 748-751 (2010).
69. K. J. Ressler, B. O. Rothbaum, L. Tannenbaum, P. Anderson, K. Graap, E. Zimand, L. Hodges, M. Davis, Cognitive enhancers as adjuncts to psychotherapy: Use of D-cycloserine in phobic individuals to facilitate extinction of fear. Arch. Gen. Psychiatry 61, 1136-1144 (2004).
70. M. Ayalew, H. Le-Niculescu, D. F. Levey, N. Jain, B. Changala, S. D. Patel, E. Winiger, A. Breier, A. Shekhar, R. Amdur, D. Koller, J. I. Nurnberger, A. Corvin, M. Geyer, M. T. Tsuang, D. Salomon, N. J. Schork, A. H. Fanous, M. C. O'Donovan, A. B. Niculescu, Convergent functional genomics of schizophrenia: From comprehensive understanding to genetic risk prediction. Mol. Psychiatry 17, 887-905 (2012).
71. T. D. Cannon, K. Cadenhead, B. Cornblatt, S. W. Woods, J. Addington, E. Walker, L. J. Seidman, D. Perkins, M. Tsuang, T. McGlashan, R. Heinssen, Prediction of psychosis in youth at high clinical risk: A multisite longitudinal study in North America. Arch. Gen. Psychiatry 65, 28-37 (2008).
72. M. Marshall, J. Rathbone, Early intervention for psychosis. Cochrane Database Syst. Rev. 6, CD004718 (2011).
73. E. O. Arnarson, W. E. Craighead, Prevention of depression among Icelandic adolescents: A 12-month follow-up. Behav. Res. Ther. 49, 170-174 (2011).
74. S. M. Paul, D. S. Mytelka, C. T. Dunwiddie, C. C. Persinger, B. H. Munos, S. R. Lindborg, A. L. Schacht, How to improve R&D productivity: The pharmaceutical industry's grand challenge. Nat. Rev. Drug Discov. 9, 203-214 (2010).
75. C. G. Begley, L. M. Ellis, Drug development: Raise standards for preclinical cancer research. Nature 483, 531-533 (2012).
76. J. L. Warner-Schmidt, K. E. Vanover, E. Y. Chen, J. J. Marshall, P. Greengard, Antidepressant effects of selective serotonin reuptake inhibitors (SSRIs) are attenuated by antiinflammatory drugs in mice and humans. Proc. Natl. Acad. Sci. U.S.A. 108, 9262-9267 (2011).
77. M. Allison, NCATS launches drug repurposing program. Nat. Biotechnol. 30, 571-572 (2012).
78. A. Mullard, Drug repurposing programmes get lift off. Nat. Rev. Drug Discov. 11, 505-506 (2012).
79. F. Prinz, T. Schlange, K. Asadullah, Believe it or not: How much can we rely on published data on potential drug targets? Nat. Rev. Drug Discov. 10, 712-713 (2011).
80. S. C. Landis et al., A call for transparent reporting to optimize the predictive value of preclinical research. Nature doi: 10.1038/nature11556 (2012).
81. T. C. Norman, C. Bountra, A. M. Edwards, K. R. Yamamoto, S. H. Friend, Leveraging crowdsourcing to facilitate the discovery of new medicines. Sci. Transl. Med. 3, 88mr1 (2011).
82. J. A. Wagner, M. Prince, E. C. Wright, M. M. Ennis, J. Kochan, D. J. Nunez, B. Schneider, M. D. Wang, Y. Chen, S. Ghosh, B. J. Musser, M. T. Vassileva, The Biomarkers Consortium: Practice and pitfalls of open-source precompetitive collaboration. Clin. Pharmacol. Ther. 87, 539-542 (2010).
83. M. Goldman, Reflections on the Innovative Medicines Initiative. Nat. Rev. Drug Discov. 10, 321-322 (2011).
84. B. G. Druss, L. Zhao, S. Von Esenwein, E. H. Morrato, S. C. Marcus, Understanding excess mortality in persons with mental illness: 17-year follow up of a nationally representative U.S. survey. Med. Care 49, 599-604 (2011).
85. M. DE Hert, V. Schreurs, D. Vancampfort, R. VAN Winkel, Metabolic syndrome in people with schizophrenia: A review. World Psychiatry 8, 15-22 (2009).